Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GZPHF · as of 2026-06-09
Financial statements
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $75.45B | $74.99B | $75.52B | $70.79B | $69.01B |
| Cost of Revenue | $63.99B | $62.47B | $61.33B | $57.51B | $55.78B |
| Gross Profit | $11.46B | $12.52B | $14.19B | $13.28B | $13.23B |
| Gross Margin %(computed) | 15.18% | 16.70% | 18.79% | 18.76% | 19.17% |
| Operating Expenses | |||||
| R&D Expenses | $0.59B | $0.76B | $0.78B | $0.82B | $0.87B |
| G&A Expenses | $0.00B | $0.57B | $0.60B | $0.55B | $0.48B |
| Total Operating Expenses | $8.43B | $8.92B | $9.07B | $8.73B | $8.85B |
| Operating Income | $3.02B | $3.60B | $5.12B | $5.07B | $4.79B |
| Operating Margin %(computed) | 4.01% | 4.80% | 6.78% | 7.17% | 6.93% |
| Interest Income | $0.64B | $0.40B | $0.49B | $0.63B | $0.56B |
| Interest Expense | $0.42B | $0.42B | $0.47B | $0.43B | $0.42B |
| Income Before Tax | $3.59B | $3.61B | $5.11B | $5.04B | $4.72B |
| Income Tax Expense | $0.61B | $0.61B | $0.85B | $0.79B | $0.75B |
| Net Income | $2.91B | $2.84B | $4.06B | $3.97B | $3.72B |
| Net Margin %(computed) | 3.85% | 3.78% | 5.37% | 5.60% | 5.39% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.82 | $1.74 | $2.49 | $2.44 | $2.29 |
| Wtd Avg Shares | 1.63B | 1.63B | 1.63B | 1.63B | 1.63B |
| EBITDA | $3.95B | $4.90B | $6.46B | $6.27B | $5.76B |
| EBITDA Margin %(computed) | 5.24% | 6.54% | 8.55% | 8.86% | 8.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited data
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) Income Statement
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GZPHF reported revenue of $75.45B, gross profit of $11.46B (gross margin 15.18%), and net income of $2.91B — a net profit margin of 3.85%.
Frequently asked questions
GZPHF · 4 questionsGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) reported revenue of $75.45B for 2025, up 0.6% year-over-year.
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09